March 3, 2011

Zacks Small-Cap Research

Brian Marckx, CFA
bmarckx@zacks.com
Ph (312) 265-9474

www.zacks.com
111 North Canal Street, Chicago, IL 60606

CryoPort Inc (CYRX-OTC)

CYRX: Initiating at Outperform

Current Recommendation	**Outperform**
Prior Recommendation	N/A
Date of Last Change	03/02/2011
Current Price (03/03/11)	$1.20
Target Price	**$3.85**

OUTLOOK

CryoPort's target markets are currently worth up to $500MM and growing at 20%+ per year. We have not been able to poke any significant holes in their product or business model and believe it is conceivable that CryoPort Express could soon become the industry standard for shipping frozen biological material. Despite the anticlimactic launch, customer feedback has been highly favorable. Deals with FedEx and DHL are in place and could spark a ramp in customer flow. Scalable business model means earnings and EPS could accelerate quickly with greater customer acceptance. Although our model reflects a more modest ramp compared to management's expectations, we believe the current share price still considerably undervalues the company. We are initiating at Outperform. Our price target is $3.85.

SUMMARY DATA

52-Week High	**$2.30**
52-Week Low	**$0.43**
One-Year Return (%)	**N/A**
Beta	**N/A**
Average Daily Volume (sh)	**87,244**
Shares Outstanding (mil)	**27**
Market Capitalization ($mil)	**$32**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**N/A**
Insider Ownership (%)	**N/A**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2011 Estimate	**N/A**
P/E using 2012 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**N/A,**
Type of Stock	**N/A**
Industry	**#Linkerror**

ZACKS ESTIMATES

Revenue
(in '000s of $)

	Q1 (June)	Q2 (Sep)	Q3 (Dec)	Q4 (Mar)	Year (Mar)
2011	152 A	124 A	100 A	108 E	484 E
2012					3,898 E
2013					24,275 E
2014					54,682 E

Earnings per Share

	Q1 (June)	Q2 (Sep)	Q3 (Dec)	Q4 (Mar)	Year (Mar)
2011	-$0.16 A	-$0.15 A	-$0.11 A	-$0.08 E	-$0.45 E
2012					-$0.21 E
2013					$0.05 E
2014					$0.25 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

© Copyright 2011, Zacks Investment Research. All Rights Reserved.

KEY POINTS

- Packaging of frozen shipments of biological material is currently dominated by dry ice in Styrofoam containers. Process is not only a hassle, it is costly and often results in specimen spoilage.
- Liquid nitrogen containers are not new but have yet to gain traction as a result of cost, reliability issues and no meaningful improvement to the "hassle" element.
- CryoPort's unique offering aims to solve all the issues inherent with dry ice and competing liquid nitrogen containers.
- CryoPort's next-generation liquid nitrogen container combined with its web-based billing and tracking system provides a hassle-free, reliable and low cost outsourcing solution for cold chain shipping.
- No other company offers anything directly similar.
- Partnership deals in place with Federal Express and DHL Express. Quotes from FedEx's press release in announcing the deal with CryoPort included;
    - Raj Subramaniam, FedEx's senior VP of global marketing; *"It is truly a complete solution that enhances the current services we provide our health care customers, giving them an even greater peace of mind".*
    - Carl Asmus, FedEx's VP for international development for FedEx Health Care Solutions; *"Deep frozen is a very fast growing area, and it's becoming a very significant area for us. As we see these more and more complex technologies and medicines being developed, they're requiring more robust and temperature-sensitive shipping solutions."*
    - Carl Asmus (regarding the significant shift of clinical trials being moved overseas); *"It requires a far more reliable shipping solution and that's why it* (i.e. – CryoPort's offering) *just plays into FedEx's strengths in regard to our network and reliability."*
- Target market is estimated at $400 million - $500 million and expected to grow at 20% or more over the next several years. Clinical trials moving overseas is creating more demand for frozen shipping containers with long holding times – CryoPort should be a direct beneficiary.
- CryoPort launched its CryoPort Express shipping solution in late 2010. Sales ramp has been slower than anticipated although customer feedback has been overwhelmingly positive.
- Convincing prospective customers to abandon legacy shipping methods will be key to increasing adoption. Customer satisfaction and retention appears to be very high which should bode well for accelerating adoption rate.
- CryoPort, along with FedEx sales reps, have recently ramped up their sales and marketing efforts – fruits of which we expect to begin seeing within the next 6 – 9 months.
- CryoPort's scalable business model means cash flow and earnings could accelerate quickly.

BUSINESS

CryopPort, Inc. has developed what it believes is a "game-changing solution to the challenge of shipping biological materials" which require a frozen condition. CryoPort's offering includes CryoPort Express Shipper, a proprietary liquid nitrogen container with long holding periods and CryoPortal, a web-based ordering, tracking and monitoring system.

CryoPort's cold chain frozen shipping system targets customers in the life sciences industry which ship biological specimens such as vaccines, blood, cancer tissue and stem cells that must be kept at extremely low temperatures during transport, often over several days or even weeks, in order to prevent cell death.

Currently, the vast majority of frozen biological material is shipped using dry ice, which has a relatively short holding time and is handling-intensive, among having other drawbacks. CryoPort's container addresses all the deficiencies of dry ice, but more importantly, combined with their web portal, provides life sciences companies a self-contained outsourcing solution to their frozen shipping needs. There are a select number of other companies which offer liquid nitrogen shipping containers, but none, to our knowledge, that offer the combination of a next-generation container and robust service infrastructure similar to CryoPort's Express solution.

The annual market specific to CryoPort's offering is estimated at $400 - $500 million and projected to grow at about 20% over the next several years. Market growth is largely being driven by more clinical trials moving overseas, which often require long shipping and extended holding times.

In 2010 CryoPort signed separate agreements with Federal Express (FedEx) and DHL Express (DHL) which provide customers with preferred pricing. These carrier collaborations also greatly enhance and expand the company's marketing message, efforts and reach. CryoPort commenced roll-out of its shipping system in late 2010 but due to unanticipated delays with integrating IT systems with FedEx and slower than expected immediate acceptance among potential customers, the launch has been somewhat anti-climactic.

Since then, management has ramped up their marketing efforts including meeting with prospective customers, making presentations at life sciences events, hiring additional sales staff and training FedEx's sales people. Despite the slower than anticipated initial ramp in client flow, by all accounts customer feedback has been overwhelmingly positive which should help to accelerate the rate of acceptance going forward. FedEx also appears to be a big believer in CryoPort's system, noting in a January 2011 press release that, "It is truly a complete solution that enhances the current services we provide our health care customers, giving them an even greater peace of mind".

FROZEN BIOLOGICAL MATERIAL SHIPPING

Pharmaceutical companies and clinical research organizations (CROs), among other life sciences companies, use frozen shipping to transport biological drugs and live specimens. These materials must be kept at low temperatures (sometimes as low as -150° C) over the duration of transport in order to ensure the integrity of the samples.

Clinical trials in connection with development of new drugs require that biological samples be shipped from the point of collection (typically a hospital or clinic) to the labs where the specimens are analyzed. Oftentimes a single clinical trial will use numerous patient sites scattered over different parts of the country or the world. This can require long shipping times for the patient samples to reach the testing labs.

Clinical trials can be extraordinarily expensive and sometimes take years to complete. In addition, based on the typically strict protocol and analytical procedures of these trials, patient samples can not be redone if lost or damaged. As a result it is critical that the specimens be maintained at pre-specified temperatures in order to ensure they are not ruined.

Biologic drug (i.e. – made from a living organisms) development has surged over the last several years and is expected to grow significantly faster than that of chemical drugs. This, along with much of the manufacturing of biologics recently moving overseas, has increased the demand for reliable frozen shipping with long holding periods.

Infectious materials must be packaged and shipped according to strict regulations. Infectious materials are classified by international regulations as those that are known or reasonably believed to cause disease in humans or animals. Human specimens containing serious diseases (for example HIV-infected blood) are classified as infectious substances and must be shipped frozen and packaged so as to reduce the risk of human exposure.

Artificial insemination, as it relates to both humans and animals, typically involves the transport of semen to the insemination site. Human and animal semen must be stored and shipped at cryogenic (-150° C) temperatures. These extremely low temperatures can only be attained with the use of liquid nitrogen (dry ice sublimation temperature is only -79° C).

DRY ICE PACKAGING

The most common method today for packaging frozen materials involves the use of dry ice in a Styrofoam container. In general, dry ice can keep a biological sample frozen for only one or two days. This poses a problem, especially for international shipments with long transport times. The solution, which has been to re-ice the packages at points during transportation, involves extra handling and thus, additional expense. The need to re-ice also introduces other possible complications including the potential that dry ice is not available where or when needed or is not possible due to flight cancellations or other unexpected circumstances. If not re-iced in time, biological samples can be tainted and, therefore, unusable. Temperature excursions, which are common with dry ice shipments, can also be detrimental to the health of a specimen sample. CROs and pharmaceutical companies have a very significant interest (i.e. – money) in completing clinical trials as soon as possible and unusable patient samples only hinder progress and add time and cost.

DRY ICE *PROBLEMS*

- ***1 – 2 DAY HOLDING TIME*** – international shipments often require lengthy holding times. This means packages need to be re-iced. Re-icing is costly and if not re-iced in time, contents will spoil.

- ***TEMPERATURE EXCURSIONS*** – temperature fluctuations are common with dry ice, especially during re-icing. Many specimens require near-constant temperature in order to retain integrity.

- ***HASSLE*** **–** the typical process followed by life sciences companies when shipping using dry ice involves ordering containers, ordering dry-ice, following special dry-ice handling instructions, filling out complicated shipping paperwork (dry-ice is considered a "dangerous good" and requires specific paperwork), contacting specialty carriers and then hoping the contents do not spoil before they reach their destination.

- ***DANGEROUS GOODS*** – some carriers and countries will not accept packages which use dry ice as a refrigerant.

- ***ENVIRONMENTAL IMPACT*** **–** Styrofoam containers are largely the packaging of choice used with dry ice – much of this packaging is single-use only and thrown away after one shipment. By some estimates Styrofoam takes up 25% of U.S. landfill space with insulating packaging a major contributor to this. Dry ice is also not environmentally friendly as it evaporates as a greenhouse gas (carbon dioxide).

CRYOPORT's *SOLUTION*

- ***LONG HOLDING TIME*** **–** CryoPort's Shipper has a 10+ day holding time. - long enough for almost all international shipments from origin to destination. No special handling is required which reduces cost.

- ***STABLE TEMPERATURE*** **–** unlike dry ice, CryoPort's LN_2 container maintains a constant temperature. Temperature monitoring device affords confidence that temperature of specimen did not fluctuate.

- ***OUTSOURCING SOLUTION*** - CryoPort understands the hassles involved with shipping using dry ice. They developed their system as a complete outsourcing solution. Ease and reliability of their system affords customers less headaches and added piece of mind.

- ***NON-HAZARDOUS*** – CryoPort's Shipper is classified as "non-hazardous" by the IATA. The containers do not risk being prohibited entry on certain carriers or into certain countries. They also do not require any special labeling.

- ***ENVIRONMENTAL FRIENDLY*** - LN_2 evaporates harmlessly. CryoPort's Shippers are reusable and recyclable.

PRODUCTS

CryoPort's outsourcing shipping solution encompasses a proprietary container along with an IT interface. The combination which the company believes affords customers (initially expected to be clinical trial related) a more reliable, less time consuming, easier and (potentially) less costly alternative to shipping with the use of dry ice and specialty couriers.

CryoPort Express Shippers

CryoPort Express® Shippers ("Shippers") are reusable dewar flasks made from aircraft-grade aluminum with a chamber for holding biological specimens. The patented containers use dry vapor liquid nitrogen (LN_2) as a refrigerant. The flask is similar to a thermos bottle in that it is designed to reduce heat conduction and convection.

Inside the chamber can be placed as many as 75 specimen vials. Surrounding the container's chamber is a low density, porous foam which fully absorbs the LN_2. Cold vapor emanating from the foam cools the specimen inside the chamber to as low as -150° C. The vapor then slowly evaporates out of the container's vapor plug. This proprietary design – in which the liquid nitrogen is absorbed by the foam, prevents the liquid nitrogen from spilling – regardless of how the container placed (i.e. – upside-down, on its side, etc.). CryoPort believes this proprietary spill-proof design affords a significant advantage over competing shipping containers

The specimen chamber is closed with a cap. A very high vacuum is created in the space between the outer and inner aluminum shell of the flask and a second cap is used to enclose the liquid nitrogen and specimen holding container. The dewar is wrapped insulating and cushioning materials and placed in a disposable, spill-proof package for shipment. CryoPort notes that their Shipper provides cooling for ten days or more and is relatively lightweight (~22 lbs.) – both of which it believes are other significant advantages (along with "spill-proofness") over competing products or methods of cold chain shipping.


The International Air Transport Association (IATA) is a global body that represents the airline industry. The IATA is made up of a consortium of airlines which publishes the "IATA Dangerous Goods Regulations" manual, a globally accepted field source reference for shipping of dangerous goods and hazardous materials. IATA has specific regulations regarding the packaging requirements of shipping of diagnostic specimens and infectious substances (covered by IATA Packaging Instructions 650 and 602, respectively). If a package does not meet these requirements, it can not be shipped by air. CryoPort's Shippers meet both of these requirements which essentially means it can be used to ship any type of biological material. This includes live cell pharmaceutical products such as cancer vaccines, diagnostic materials, semen and embryos, infectious substances and other items that require continuous exposure to frozen or cryogenic temperatures.

CryoPort Express Shippers are designated as "dry shippers" by the International Air Transport Association (IATA). As opposed to dry ice which must be labeled as "dangerous goods" and packaged in a way that permits the release of a build-up in gases, CryoPort's Shippers are considered "non-hazardous" by the IATA and therefore do not require any special labeling. The distinction is meaningful as: 1) airlines have discretion to refuse to carry certain cargo and are more likely to do so for those classified as "dangerous goods" 2) some countries refuse to accept shipments containing dry ice 3) the process of labeling "non-hazardous" materials is more simple which makes the shipping process easier.

There are other companies that offer LN_2 containers but (as we detail under "Competition" below) there can be important differences in functionality between the various containers on the market. CryoPort has designed their Shipper and patented certain of its components to address what it believes have been significant deficiencies of other LN_2 containers. CryoPort owns three patents on its Shipper relating to the absorption foam, secondary packaging, and dewar materials and design – which are integral to its relatively light weight and "spill-proofness".


CryoPort noted in recent presentations that, due to customer interest, they are working on development of a larger container that would have a capacity greater than the current 75-vial model. The company did not offer details relative to where they are in the development process or potential launch timelines for the product.

Disposable, spill-proof package



CryoPort, Inc.

CryoPort Express Shipper




CryoPort, Inc.

CryoPort Express Portal

CryoPortal™ is the company's proprietary web-based ordering, tracking and monitoring system. It allows customers as well as CryoPort's customer service personnel to request a shipment and track its progress through the transport process. CryoPortal automates entry of orders, prepares customs documentation and tracks the shipment through to its destination. It will also alert customers and customer service if a shipment encountered unexpected delays – allowing for rerouting if necessary. The system is also integrated with the tracking systems of CryoPort's carrier partners (i.e. – FedEx and DHL), allowing for the seamless translation of scan codes and shipping and tracking information into the CryoPortal's interface.

The IT behind CryoPortal was built by KLATU Networks, a company that specializes in development of cold storage information networks. KLATU and CryoPort spent significant time in developing CryoPortal to ensure ease-of-use and high functionality and utility. CryoPortal integrates the multiple steps involved in the shipping into a one-stop-shopping experience – which CryoPort believes can reduce administrative costs and headaches associated with less automated processes. CryoPort also notes that its web portal can "detect and sometimes anticipate delays in the shipping process, often before the customer of the shipping company becomes aware of it."

CryoPortal web portal






CryoPort, Inc.

Smart Pak
CryoPort's Express Smart Pak is a data logger device which can be included with the Shipper to monitor the temperature of the specimen. The device uses a probe located in the vapor plug of the container. When the Shipper arrives at its destination, the Smart Pak is removed and the temperature data can be reviewed, downloaded and sent to the customer in PDF format. Smart Pak is a value-added feature and provides assurance that temperature of the specimens remained at acceptable levels, ensuring there was no degradation in the integrity of the contents.

Smart Pak was introduced during 2010. CryoPort continues with development and expects to incorporate additional functionality into the device during 2011 including the ability to wirelessly transmit information of the package including location, temperature, tilt, vibration and humidity.


Smart Pak data logger



CryoPort, Inc.

Accessories
CryoPort also offers for sale sterile vials and aluminum canes which hold the vials during transport. The canes hold up to five vials each and up to fifteen canes can be placed in the CryoPort Shippers.

Cryovial



CryoPort, Inc.

Canes



CryoPort, Inc.

CRYOPORT EXPRESS SHIPPING PROCESS

CryoPort designed its products and processes to be an outsourcing solution for its customers frozen shipping needs so those companies can spend less time and money on preparing and monitoring shipments and more resources on value-added aspects of their respective businesses.

1.) **Order is placed via CryoPortal for CryoPort**

2.) **CryoPort arranges to send CryoPort Express Shipper, already charged with LN_2, next-day air to point of origin (i.e. – where specimen will be loaded)**


3.) **Prior to shipping out the container, CryoPort prepares and attaches all necessary shipping paperwork (air bill, commercial invoice, regulatory labels, etc.) – this includes all the shipping paperwork for transport to the point of origin (i.e. - from CryoPort's warehouse to point where specimen will be loaded) as well as all the paperwork necessary to ship from point of origin to its destination and back again to CryoPort**

4.) At point of origin, the brown shipping carton is removed. Specimens (for example, human blood samples collected at a hospital for clinical trial purposes) are then loaded into the CryoPort Shipper

5.) Personnel at point of origin seal box (box shipping label already prepared and attached prior to being shipped from CryoPort) and make package available for pick up by cargo carrier

6.) Personnel at point of destination unload material, close box and make it available for shipment to CryoPort by cargo carrier

7.) Upon arrival back to CryoPort, the box is recycled and the flask refurbished and then reused



BUSINESS MODEL – MOSTLY SCALABLE

Revenue is generated through lease of the containers on a per-use basis. As a significant portion of costs are either fixed (containers) or semi-fixed (servicing customer flow), the business should be fairly scalable. Cost of the containers is capitalized and depreciated (runs through COGS) over three years. As of 12/31/2010 the shipping containers comprised 83% of total PP&E.

CryoPort sources individual components of its products from third parties and maintains a facility near San Diego where it assembles the shipping containers. They also currently have two refurbishing facilities from which the containers are shipped after used for specimen delivery, refurbished and then reused. The company expects to add additional refurbishing facilities as new customers come online – likely located in overseas locations such as Asia and Brazil. As these facilities are rather rudimentary, incremental costs associated with these sites should be relatively minor.

CARRIER PARTNERSHIPS

As we detail under "Competition", several air carriers have recently launched specialty cold chain logistics and shipping services due to increasing demand. CryoPort, through agreements with two of the world's largest cargo carriers, should be able to directly benefit from the surge in clinical trial activity, especially overseas, through leveraging these carriers' geographic reach, marketing muscle and logistics capabilities. CryoPort did not release specifics about pricing through these agreements but did note publicly that customers shipping through FedEx and DHL would receive "preferred pricing". CryoPort hopes to sign agreements with other carriers in the future.

Federal Express
In January 2010 CryoPort signed an agreement with FedEx whereby FedEx will lease CryoPort's Express Shippers and other products such as its Smart Pak data logger.

All orders can be placed either through CryoPort's CryoPortal or FedEx.com and FedEx will lease the Shippers from CryoPort for each order. FedEx is responsible for delivering the Shipper from CryoPort's facility to the customers' address and finally back to CryoPort. FedEx monitors the container throughout transit and can intervene in the event of delays and reroute the package if necessary.

FedEx will pay CryoPort a fixed fee per lease transaction (up to 14 days), the amount dependent on to and where the Shipper will be shipped. FedEx is not required to lease a minimum number of Shippers from CryoPort. Per the agreement CryoPort is required to maintain shipper recycling centers in Asia, Europe and South America and is responsible for supplying and recharging all containers.

FedEx launched the program in January 2011 under the name, "FedEx Deep Frozen Shipping Solution" as part of its FedEx Healthcare Solutions business which specifically targets customers in the pharmaceutical and biotech industries and caters to clinical trials applications. FedEx's sales representatives will market the service to their customer base.

FedEx issued a press release on January 24, 2011 announcing launch of the program. Raj Subramaniam, FedEx's senior VP of global marketing, in describing CryoPort's system said, "It is truly a complete solution that enhances the current services we provide our health care customers, giving them an even greater peace of mind". Carl Asmus, FedEx's VP for international development for FedEx Health Care Solutions, said, "Deep frozen is a very fast growing area, and it's becoming a very significant area for us. As we see these more and more complex technologies and medicines being developed, they're requiring more robust and temperature-sensitive shipping solutions." Relative to the significant shift of clinical trials being moved overseas, Asmus commented, "It requires a far more reliable shipping solution and that's why it (i.e. – CryoPort's offering) just plays into FedEx's strengths in regard to our network and reliability."

FedEx and CryoPort began marketing the partnership and making sales calls to potential customers in late 2010. Management noted in recent investor presentations and conference calls that they have been targeting life sciences companies in cities with a big biotech and pharma presence as this is where they think they can be most productive initially.

DHL Express
CryoPort announced an agreement with DHL in September 2010. The agreement is very similar to the deal with FedEx, offering preferred pricing and allowing customers access to CryoPort's web portal through integration of the system into the carriers' IT systems. It differs slightly however, as DHL will not market CryoPort's service (whereas FedEx will.

As of CryoPort's last investor update call the company was still working with DHL in integrating their web portal with DHLs tracking and billing system. CryoPort's 10-Q for the period ending December 31, 2010 (filed February 22, 2011) noted that they expected to have integration of the systems completed by fiscal Q4 2011 (March 31, 2011) – this is consistent with the timeframe management indicated on their December 16, 2010 investor update conference call.

MARKETS

CryoPort notes in their public filings and in presentations that they expect to eventually target a number of different categories of customers and applications including those related to food, bio-terrorism, environmental samples and semiconductors. These are more of "back-burner" markets at the moment and we expect the majority of near-term interest in CryoPort Express to come from the life sciences industry including pharmaceutical, biotechnology and clinical research companies. Fertility clinics also fall into the life sciences category and offer a very captive market given the fact that semen must be shipped at cryogenic temperatures (thus disqualifying dry ice as an option) but at an estimated 50k doses shipped annually (estimate taken from CryoPort's 10-K), they represent a relatively insignificant portion of total cold-chain shipping volume.

Current Market


CryoPort's target market is a niche estimated to be worth between $400 million - $500 million in the broader ~$5 billion cold chain shipping category. CryoPort's market represents small specimen size that can benefit from being kept in a frozen state – and more specifically, that require long holding periods (i.e. – international shipments). While we have found nothing that documents the expected growth for CryoPort's specific market, we believe certain catalysts which are expected to drive growth of the overall cold chain shipping category will benefit CryoPort's niche as well. Based on these estimates, we think it is reasonable that CryoPort's target market can be expected to grow at 20% or more annually over the next several years.

Life Sciences Cold Chain Shipping

Cold chain shipping is somewhat of a broad category and includes a fairly diversified participant base from several industries including transportation, packaging and logistics - in addition to a variety of life sciences companies. U.S. and international regulatory bodies also play a part. There are also several processes involved which can differ based on the handling requirements of the material being shipped, cost and time considerations, regulations and destination of the shipment, among other potential factors. Recent developments in the pharmaceutical and biotechnology industries have resulted in a number of changes to these links within cold chain shipping and have created opportunities for many of its participants. It is important to understand when considering CryoPort's opportunity and target markets, however, that much of the cold chain shipping market is confined to materials that need to be kept cold but not frozen. This disqualifies CryoPort's Shipper, which maintains specimens at cryogenic temperatures, as a shipping option. Nonetheless, we expect recent developments to be catalysts in expanding the entire cold chain shipping market – including those related (directly or indirectly) to CryoPort's offerings.

Pharmaceutical Commerce, a publication focused on the processes involved in getting new drugs to market, recently published a study on cold chain shipping related to life sciences called "Biopharma Cold Chain Sourcebook 2010". The report estimates that cold chain shipments accounted for about $5 billion (or ~12%) of the roughly $43 billion that was spent on life sciences shipping during 2008. Of this, about $2 billion was for cold chain packaging and instrumentation. Instrumentation includes temperature monitoring devices.

Fig. 2. $5 billion was spent on global cold-chain logistics in 2008, in a total biopharma logistics market of $43 billion



www.pharmaceuticalcommerce.com

Fig. 3. Cold-chain logistics spending will expand from $5.1 billion in 2008 to $6.6 billion by 2011



www.pharmaceuticalcommerce.com

Authors of the report expect demand for cold chain shipping to grow significantly over the next several years, driven in large part to expanding international vaccination programs and a shift away towards development of more biological drugs. According to *Pharmaceutical Commerce*, this will help push demand for cold chain shipping up to

$6.6 billion by the end of the current year. Much of this growth is expected to come from outside the U.S. with shipping to/from Asia and emerging markets forecast to grow by about 50% and 33%, respectively.

Distribution / Clinical Trials

Life sciences companies use cold chain shipping for two major purposes: 1) distribution of commercialized drugs and, 2) clinical trial related purposes for drug candidates under development. The industry report does not differentiate between the expected growth in spending on distribution versus that of clinical trials. Nor does it specifically differentiate between spending on the type of cold chain packaging. As a result, we have to make some generalizations about how this may benefit CryoPort.

While we believe CryoPort can directly benefit from increased clinical trial activity, cold chain drug distribution typically involves the use of large containers which may limit their exposure to that segment of the market. We also note that CryoPort's liquid nitrogen shippers cater to drugs that need to be in a frozen state during transport – a condition that not all biological drugs require.

Vaccines - distribution

A catalyst to the growth in vaccines has been philanthropic efforts such as the Bill and Melinda Gates foundation which have been focused on the eradication of infectious diseases in many third world countries through greater access to medicines.

While the portion of the predicted growth in cold chain shipping over the next few years related to vaccine distribution could be a boon for certain companies that cater to the long-haul segment, it may not translate into a comparably significant opportunity for CryoPort. We think some of the greatest beneficiaries in the cold chain system will be those that provide large capacity cold (but not necessarily frozen) storage with long holding times. There are several companies that participate in this portion of the market, some of which have specific collaborations, partnerships or joint-ventures with large air cargo carriers.

While some vaccines need to be kept frozen in order to maintain their effectiveness, most vaccines need to be maintained at temperatures between 2°C - 8°C (35°- 46°F) and can not be exposed to freezing temperatures. And more recently, vaccines that can be kept at room-temperature have been introduced. CryoPort's target markets are clearly those that require materials to be maintained at sub-freezing temperatures. CryoPort's Shippers, with a current (as noted they are working on developing a higher-capacity container) capacity of 75 vials, also do not cater to distribution related to mass vaccination programs. This isn't to imply that CryoPort can not or will not benefit from the surge in vaccine manufacturing, especially as new vaccines are developed that may require a frozen state – only that we do not think CryoPort will see much of an initial significant and direct benefit from an increase in distribution demand from the growth in the global vaccine market.

Clinical Trials

Major pharmaceutical companies have a major problem. Reliance on chemical drugs with finite patent lives which are relatively easy to copy and generacize has recently sent many big pharmas (Pfizer, Sanofi-Aventis, Merck, Eli Lilly, among others) scrambling to find new, more stable sources of revenue. Consolidation in the industry has been rampant over the last few years, driven in large part by the desire to increase development of biological drugs – which are inherently very difficult to copy.

By some estimates, 50% of all new drugs will be biologics by the year 2015 with a big part of this growth forecasted to come from vaccines. Stem cell research has grown substantially over the last few years and is also expected to be a major area of interest for biotech companies focused on areas such as cancer and birth defects. While controversy remains regarding the use of stem cells for research purposes, the area is gaining support both from private as well as public entities. Stem cells and cord blood are best maintained at cryogenic temperatures – for which dry ice fails and liquid nitrogen excels.

Drug development means clinical trials. Clinical trials often require that biological material be shipped in a frozen state from the point of collection (i.e. – hospital, clinic, etc.) to a lab where the specimen can be analyzed. Drug development can be extraordinarily expensive, with a significant portion of this cost related to clinical trials. As a result, many drug companies and clinical research organizations are moving clinical trial sites overseas.

A report published in the New England Journal of Medicine cited a significant increase of the number of U.S. clinical drug trials moving overseas. It noted that approximately one-third of phase III trials of major U.S. pharmaceutical companies were being run entirely outside of the United States – with many of the study sites located in Europe and Asia. Distant trial sites means potentially long transport time before specimens reach the lab – this will undoubtedly

create greater demand for frozen shipping with long holding times – and CryoPort could be a direct beneficiary of this demand for materials that are best maintained at cryogenic temperatures.

Future Markets?
CryoPort's relatively small size containers and liquid nitrogen refrigerant means that a large portion of the cold chain market is currently inaccessible. This may change in the future as the company has noted in public filings that they are working on development of larger sized Shippers and investigating "alternative phase change materials in place of liquid nitrogen (that) may be used to increase the potential markets these shippers can serve such as ambient and 2-8°C markets". While we have no visibility on the timeline or even the feasibility of CryoPort eventually introducing larger containers (the company has released little in the way development scope or progress) that could maintain temperatures in the 2°C - 8°C (35°- 46°F) range, if and when it happens, this would greatly expand their current target market – and would potentially allow them to directly benefit from the expected surge in vaccine demand (and other biologics) over the coming years.

COMPETITION

Competition to CryoPort's cold chain shipping system is represented by 1) providers of shipping containers and 2) shipping and logistics services. Our due diligence has not uncovered a competing container manufacturer that offers both a full suite (most offer no services whatsoever) of shipping services (i.e. – scheduling, tracking, monitoring, package labeling, etc.) combined with a container(s) with similar benefits of CryoPort's Shipper (i.e. – light weight, durable, long holding time, etc.). We believe CryoPort can be just as competitive against specialty courier services as a result of CryoPort's low cost business model. By contracting with large cargo carriers, including FedEx and DHL, CryoPort can offer shipping rates competitive with (and potentially significantly lower than) specialty shipping and logistics services.

CONTAINER PROVIDERS
There are two general classifications of cold chain shipping containers; active-temperature ("active") controlled products and passive-temperature ("passive") controlled products. Active devices use an electrical or mechanical means to actively control the temperature of the inside of the unit. Active container manufacturers cite longer holding times as a benefit over passive containers – while potentially true compared to most passive containers, this does not necessarily appear to be the case compared to CryoPort's container with 10+ day holding time. Passive devices, by contrast, do not have the means to adjust temperature up and down. Passive containers, in general, are less expensive and lighter weight than active containers. Lighter weight means cheaper shipping costs, but this is often achieved with the use of less durable materials – CryoPort has designed its container as lightweight without compromising durability.

CryoPort's device, which falls into the passive category, aims to offer the benefits of both active containers (longer holding times, greater durability) and passive containers (less expensive, lighter weight - cheaper shipping) without the related drawbacks. As the small size of CryoPort's Express Shipper makes it most ideally suited for clinical trial use, we focus most of our discussion on competitors' comparably sized units which would likely be used for similar purposes.

We also reiterate that CryoPort's container (and data logger) is only a portion of its cold chain shipping solution – the other, arguably just as important portion is its web portal ordering and tracking system. So if a competitor does not offer both a compelling product along with a highly functional IT support system, their aggregate value-added may fall far short of CryoPort's. In addition, cost is likely to be a consideration in a customer's decision in which vendor to use. CryoPort's business model (lease of the container and use of its ordering and tracking system) is different than many of its competitors', which largely sell their containers outright and do not provide ordering or tracking support. CryoPort's one-stop-shopping system is designed for ease, convenience and, ultimately, overall cost savings. Based on the difference in business models and potentially significant differences in shipping volumes among end-users it is difficult to make cost comparisons between vendors. However, we do believe it is reasonable to assume that time is money, and (all else equal) if CryoPort's system saves customers time compared to a competitors' offering, it would save them money.

Finally, unlike CryoPort's container which is IATA certified to ship both diagnostic specimens and infectious substances, many of the competing containers are not. As indicated earlier, the distinction is important as non-

IATA certified containers are prohibited from shipping certain materials – essentially excluding them from that portion of the market. Many life science companies will ship both non-infectious as well as infectious materials and will likely not be interested in using different containers for each – this again lends support for CryoPort's one-stop-shopping solution.



www.gokodiak.com

Kodiak Thermal Technologies offers various sizes of reusable active and passive containers. Their smallest container has a payload capacity of 1 liter and weighs 40lbs – the company's literature notes that this container is "excellent for clinical trials…." . Kodiak advertises that their active containers have holding times of at least five days. Kodiak does offer a data logger device that, according to the company's website, records internal and external temperatures which can be downloaded at the end of the trip. The company does not offer a web-based tracking and ordering product similar to CryoPort's.



www.acutemp.com

- **AcuTemp** offers a wide range of shippers including both active and passive containers. Their website notes that the longest hold time of any of their passive containers is 160 hours (~ 7 days) – that container weighs 24lbs. Their smallest active container has a capacity of 27 liters and weighs 135lbs. The company does not offer a tracking system nor a device to monitor temperature of the package contents.



www.cryogena.com

- **Cryogena**, a French company, offers a single-use passive dry shipper called Cryodrum which uses liquid nitrogen as the refrigerant. According to online literature, the container weighs approximately 15lbs. with a capacity roughly similar to that of CryoPort's Shipper. The literature notes Cryodrum has a holding time of 8 days. Cryogena does not offer a tracking system or a temperature monitoring device.




www.cryodepot.com

- **Cryodepot** appears to have containers which may be the most competitive to CryoPort's. The company claims it is the "USA's largest distributor of cryogenic equipment for scientific/medical research and educational applications". The company offers a number of different sizes of passive reusable liquid nitrogen dry shippers, including three that are in the same size range as CryoPort's Shipper. According to specifications on Cryodepot's website, one of its containers (model SC 20/12V) has a static holding time of 85 days (there is a caveat to this, however - see our discussion below of holding times) and capacity of 180 vials. That particular container weighs 52lbs. Another of its containers, and the size most similar to CryoPort's, holds 95 vials (compared to CryoPorts' 75 vials), weighs 18lbs (compared to CryoPort's 22lbs) and has a static holding time of 14 days. Cryodepot also offers a temperature monitoring device with a probe which fits through the cork of the container. Data from the logger can be downloaded at the end of the trip. Cryodepot does not appear to offer a tracking and ordering sytem, however.

We note that while Cryodepot's containers appear to have holding times longer than CryoPort's Shipper (and in the case of the 85-day container, significantly so), the comparison is not necessarily apples-to-apples due to potentially significant differences in static versus functional holding times. Cryodepot specifically notes in their online literature that their holding times are under static conditions. By contrast, CryoPort's 10+ day holding time is under functional conditions. Static holding times are measured (essentially) when the container is sitting in a room, upright and not under heat load (i.e. – not under stress of typical shipping conditions). Functional holding times are measured under use and containing samples. Static and functional performance can significantly differ, in large part due to tilting of containers during shipment which can cause the liquid nitrogen to evaporate much more rapidly than when sitting upright. CryoPort designed its containers in a way to specifically address this issue, resulting in relatively long functional holding times. Cryodepot mentions in their literature that their containers employ a certain absorbent material that results in "spill-free shipping" and offers "the maximum holding time." But Cryodepot's online literature includes a chart (at left) that indicates that when their containers are placed upside-down and on their side that their holding times are only approximately 5% and 35% of the stated static holding times. So accordingly, their container with a static holding time of 85 days may have a functional holding time of as short as 4 days.

Cryodepot



www.cryodepot.com

We also believe that CryoPort's web-portal order and tracking system is a significant portion of the value-added proposition that CryoPort's total cold chain system offers – which Cryodepot lacks. As a result, we expect CryoPort to be very competitive to Cryodepot's offerings, regardless of potential differences in holding times.



- **Taylor-Wharton** offers passive reusable liquid nitrogen shippers which also appear like they could be competitive with CryoPort's. Two of the smaller containers hold between 85 and 100 vials, weigh approximately 20lbs. and have listed "working" holding times of 11 to 17 days. The company notes that they do offer temperature data loggers but it does not appear that they offer an ordering and tracking system.

www.taylorwharton.com

SPECIALTY LOGISTICS

The other side of the competitive spectrum is the service side of the business – this comes mostly from specialty logistics organizations. **World Courier** is the largest specialty courier service for the pharmaceutical industry – the company claims that they are involved in transportation and logistics with 80% of the world's clinical trials which require specialty courier service. The company has over 140 offices throughout the world and offers "comprehensive clinical trial services" including transportation scheduling from collection site to lab, expertise in cold chain handling, dry ice replenishment, shipment monitoring with real-time tracking and customs clearance. The company offers a proprietary clinical trials data management system which can, according to World Courier, "take clinical trial logistics management to an entirely new level" and "can proactively anticipate and prevent costly transportation problems that are so often unavoidable when conducting studies".

CryoPort acknowledges that these specialty carriers offer a competitive threat but due to the relatively high cost of these service providers, that CryoPort's system can provide a cheaper alternative with no compromise to service, ease or convenience. In their recent investor presentation, CryoPort noted that a study done by Quest Diagnostics showed that CryoPort's Express Shipping system cost approximately 20% less than compared to World Courier in shipping to 21 Asian cities.

With the recent surge in cold chain shipping demand, large air carriers have been launching their own specialty pharmaceutical shipping services. *Pharmaceutical Commerce* notes that in less than three years' time the number of airlines launching pharmaceutical product offerings has grown from four to more than a dozen. Some of these include

- **American Airlines** recently teamed up with **Envirotainer**, a manufacturer of large cold chain shipping containers, in launching their ExpediteTC service which is focused on temperature-controlled shipping.

- **DHL** and **Lufthansa** created a joint venture called **LifeConEx** which provides an all-inclusive pricing and delivery system for temperature-sensitive biopharma products and with a specified, pre-validated container whose delivery and return to LifeConEx takes responsibility for. LifeConEx has also announced an ocean-delivery service for life sciences, brandnamed "H2Cargo".

- UPS just launched its **UPS Healthcare Logistics** service with a focus on distribution, logistics and transportation of pharmaceutical products including cold chain services.

- **FedEx Custom Critical** is an expedited (same day or overnight) air shipping service which includes temperature controlled products, handling and transportation. FedEx also recently rolled out its SenseAware tracking device in 2010. The device, in real time, monitors the location and temperature of packages. FedEx offers both the tracking device and related software to customers. FedEx's agreement with CryoPort, which FedEx markets as "FedEx Deep Frozen Shipping Solution", is part of the carriers' FedEx Healthcare Solutions business.

FINANCIAL CONDITION

Cash
As of their most recent reporting period (12/31/2010) CryoPort had $2.71 million in cash and equivalents. $91k of this is restricted and is collateral for a bank revolver. The company subsequently raised a net total of $8.20 million ($9.35MM gross) through two back-to-back private placements of common stock and related warrants. Pro forma for the recent financing, cash balance at 12/31/2010 stood at approximately $10.9 million.

Debt
As of 12/31/2010 CryoPort had approximately $4.6 million in debt outstanding. This includes $90k on a bank revolver, $1.6 million due to related parties and $2.9 million (net of $342k debt discount) on convertible debentures.

The **bank revolver** has a one year term (renewable October 2011) and is fully tapped at the current balance ($90k). It bears interest at the higher of prime plus 1.5% (4.75% as of 12/31/2010) or 5%.

Debt owed to **related parties** of $1.6 million (including accrued interest) represents funds loaned to CryoPort from 2001 through 2005 by four former members of the company's board of directors. The notes bear interest at 6% annually and require principal payments of $10k per month. Any remaining principal and any accrued interest is due on March 1, 2015. CryoPort mentions in their most recent 10-Q that through 12/31/2010 they had missed the required payments under these notes due in October, November and December of 2010 – subsequently, however, in January 2011 they made the payment due October 1, 2010. The company has a 120-day grace period to make the other two payments – and mentions in the 10-Q that, "Management expects to continue to pay all payments due prior to the expiration of the 120-day grace period. "

The $2.9 million in **convertible debentures** bear interest at 8% annually, are convertible into common stock at $3.00 per share. Interest due on the notes has been accruing. CryoPort is obligated to make monthly cash principal payments of $200k plus accrued interest beginning in March 2011. The remaining principal and accrued interest is due on August 1, 2012.

Cash Burn
Cash used in operations was $3.6 million through the first nine months of the current fiscal year (through 12/31/2010). In addition, CryoPort used $299k in cash for property and equipment (primarily for purchases related to the Shippers) over the same period. Through the most recent quarter cash used in operations and used for PP&E was $1.4 million and $28k, respectively.

We do not expect the rate of operating cash burn to change significantly in the near term. CryoPort does expect to continue to increase its inventory of containers, however. On the most recent investor conference call (December 2010) management noted that they have enough containers to satisfy approximately 6,000 shipments per month. Management also noted that they expect to become cash flow positive during the current year, and to do so would need to average about 10k – 12k shipments per month – implying they may need to double their current (as of December 2010) container inventory. We roughly estimate the additional container inventory will require $1 million - $1.5 million in cash.

OUTLOOK

Revenue through the first nine months of fiscal 2011 (December 2010) of $375k was clearly disappointing relative to what management's expectations were coming into 2010. CryoPort attributed the lackluster performance to a combination of delays in getting their IT infrastructure integrated with FedEx's, getting FedEx's sales people thoroughly trained and a lower than anticipated rate of acceptance from potential customers. While systems integration has since been finalized, significant revenue growth will not likely materialize until the other two remaining hurdles have been cleared.

While it is very difficult to gauge where CryoPort is with getting FedEx's team up to speed, CryoPort noted on their December 2010 update conference call that they have been making joint calls to potential customers. Based on this, along with our discussions with management, we believe meaningful progress is being made in getting FedEx's sales reps trained.

Increasing the rate of customer acceptance will likely be a significantly longer process. CryoPort has noted that feedback from customers that have tried their system has been overwhelmingly positive and customer retention has been very "sticky" (i.e. – once a customer tries it, they continue to use it). So the issue does not appear to be lack of customer satisfaction, but instead of getting a prospective customer to give it a try. Based on management's recent comments, they did not anticipate the lengthy process and significant amount of red-tape (i.e. – prospective customers needing to get approvals from multiple different lines of management in order to change their shipping procedures) that can be involved in recruiting new customers. CryoPort believes that they are making progress in getting all the requisite approvals from new potential customers and expects the rate of customer acceptance to begin to significantly accelerate over the next six months.

Our "Outlook" for the company is based on several assumptions, including the degree and speed of resolution of these remaining hindrances to sales growth. As a result, if reality proves to differ significantly from our current assumptions, so may the company's financial performance relative to our model.

Revenue

Revenue came in at $100k in the most recent quarter (12/31/2010). We expect revenue to remain relatively flat through the end of fiscal 2011 (March 31, 2011) as a result of FedEx reps still climbing the learning curve and red tape tie-ups with prospective customers.

CryoPort has noted that gaining all the requisite sign-offs from prospective customers can take 60 – 90 days. With CryoPort and FedEx continuously making sales calls, a meaningful amount of this business should start to roll in early fiscal 2012. Based on our rough estimates, CryoPort's containers are currently being used in about 300 shipments per month. Our model assumes this increases to 700 shipments per month in the quarter ending 6/30/2011.

Assuming the partnership with DHL gets off the ground during the first half of calendar 2011, FedEx reps are fully up to speed and progress on trudging through customers' red tape continues to be made, we think CryoPort could be making as many as 5,500 shipments per month in the quarter ending 3/31/2012. This is more conservative than management's estimate of approximately 10,000 – 12,000 shipments per month by the end of calendar 2011.

Our longer term revenue forecasts are predicated on faith that CryoPort can continue to increase rate of customer acceptance, based largely on greater visibility of the benefits of CryoPort's system over traditional frozen shipping processes. CryoPort appears to have a significantly better system of shipping frozen materials – a better mousetrap often does not result in rapid acceptance, however. Staying the course is often viewed as a safer bet than trying something new for fear that the "something new" will provide no meaningful benefit, cause disruptions or be costly. It is easier for customers to adopt the new way of doing things (i.e. – CryoPort Express) after it has been tested and proven (i.e. – "let someone else be the guinea pig" mentality). We think it is reasonable to assume that customers will jump on board at a more rapid pace as the benefits of CryoPort's offering are proven over time.

Our model assumes that CryoPort's target markets grow at an annual rate of 20% over the next several years (this may prove conservative based on independent estimates of growth of the entire cold chain shipping market) and represent approximately 8.3 million shipments per year in 2015. Our 2015 revenue estimate of $92.6 million assumes CryoPort makes about 700,000 shipments in that year, representing about 8% of its total target market. A

greater rate of acceptance or their market growing faster than our estimates could prove our estimates conservative. And based on the large size of the market, even a relatively small positive divergence in market share relative to our estimates, could have a very meaningful beneficial impact to CryoPort's revenue and EPS. We think the next twelve months will give us much greater insight into what the longer term may look like for CryoPort – and we will update our estimates if appropriate.

EPS

CryoPort's business model is fairly scalable. Typical of scalable businesses CryoPort has suffered through operating losses during early periods as meager revenue from low utilization has failed to cover fixed costs. The upside is that relatively low variable costs can result in very rapid acceleration in profitability as utilization picks up.

Through the end of the current fiscal year we expect utilization to remain relatively flat compared to the previous recent quarters. Operating expenses will likely reflect CryoPort's recent ramped-up sales and marketing efforts. We think this pushes net loss and EPS to $1.62 million and ($0.08) in fiscal Q4. For the full fiscal year ending March 31, 2011 we look for EPS of $0.45.

We think utilization will greatly ramp up beginning in the first half of fiscal 2012 and model CryoPort to fully cover COGS (which includes depreciation on the containers) beginning with the quarter ending December 31, 2011. While we believe utilization will not be high enough to fully cover operating expenses during fiscal 2012, we think EPS greatly improves and grows to ($0.21).

We model CryoPort to make 186k shipments in fiscal 2013 and with operating expense growth significantly trailing that of revenue, we think 2013 could mark the first full fiscal year of positive EPS at $0.05. We think CryoPort can grow this to $0.50 by 2015. As noted above, however, based on the rate of customer acceptance and growth of the market, this may prove to be conservative.

VALUATION / RECOMMENDATION

As we do not expect CryoPort to post positive EPS until fiscal 2013 (ending March 31, 2013) and believe valuations based on price/sales comparables are too general and can be misleading, we use a multiple of our long-term EPS estimate and discount it back to the present to value CryoPort.

Relative to an appropriate comparable for a P/E multiple – as CryoPort's business is relatively unique, there are no publicly traded directly comparable companies. As such we use the "air delivery and freight services" industry average P/E multiple of approximately 15x - air freight companies should directly benefit from the expected growth in cold chain shipping (although maybe not to the degree CryoPort should) so we think this a reasonable comparable.

As CryoPort is still very much on the front end of its roll-out, it remains very much a guess on what its future will look like. To account for this uncertainty we use a 20% discount rate which we believe appropriately reflects the inherent risks of an investment in CryoPort.

Applying a 15x multiple to our fiscal 2015 EPS estimate of $0.50 for CryoPort and discounting this back at 20% per year (through 3/31/2012) results in a valuation of approximately $3.85 per share.

A greater rate of acceptance relative to our current expectations could prompt us to raise our price target.

KEY MANAGEMENT *SOURCE: Company website*

Larry G. Stambaugh, Chairman of the Board, President and CEO

Mr. Stambaugh joined the Company's Board of Directors as Chairman on December 5, 2008 and became President and CEO for CryoPort in March 2009. He is currently a Principal of Apercu Consulting and sits on the boards of companies, including EcoDog, and BioCom. He is also currently on the Board of Directors of the Corporate Directors Forum. At Apercu, Mr. Stambaugh serves as an advisor to several private and public boards and CEOs, concentrating on strategic business direction, turnarounds and board governance. Stambaugh brings to CryoPort more than 30 years of successful experience building global businesses and setting strategies. He also brings an extensive background in life sciences and clean tech including relationships with and knowledge of Contract Research Organizations, and Biotech and Pharmaceutical companies. He earned his BBA in Accounting/Finance from Washburn University in 1969.

Catherine Doll, CFO, Treasurer and Assistant Corporate Secretary

Ms. Doll became Chief Financial Officer for CryoPort in August 2009. Ms. Doll is the owner and chief executive officer of The Gilson Group, LLC, which she founded in 2006. The Gilson Group, LLC provides financial and accounting consulting services to public companies, including Sarbanes Oxley Section 404 compliance, SEC and financial reporting, budgeting and forecasting and finance and accounting systems implementations and conversions. From 1996 to 2006, she was an associate with Resources Global Professionals, where she provided management, financial and accounting services for a variety of clients. Doll received a B.A. in Economics, with an emphasis in Accounting, from the University of California, Santa Barbara, in 1983. She has over 25 years of accounting and financial reporting experience.

Chris Campbell, Vice President, Global Business Development

Mr. Campbell became Vice President, Global Business Development for CryoPort, Inc. in March 2010. He had held the position of Executive Director, Global Business Development since joining the company in December of 2009. Campbell brings to CryoPort more than 20 years of successful executive-level experience helping companies design, develop, market and sell technologically-advanced products to multinational life science, pharmaceutical, medical device and electronics manufacturers. As Vice President of Sales and Marketing, Campbell directed the globalization of Static Control Components, Inc.'s ESD Products Division and positioned Maco Bag Corporation's Mexican subsidiary Miller Packaging to tackle the North American market. He has also consulted on an independent basis assisting firms with individual and organizational development. Mr. Campbell received his Bachelor of Science degree from the University of Oregon.

Bret Bollinger, Vice President, Operations

Mr. Bollinger became Vice President of Operations for CryoPort in February 2008. Prior to joining CryoPort, since July of 2003, He was Director of Operations and Engineering for Triangle Brass Manufacturing. From July of 2001 through July 2003, Bollinger served as a Business Process Consultant for Cardinal Health and from July of 1999 to July of 2001, he served as Operations and Order Fulfillment Manager for Ingersoll-Rand's Falcon Lock Company. Bret has extensive background in domestic and international manufacturing environments. In addition, he has experience in new product design and implementation. Mr. Bollinger holds a Bachelor of Science in Mechanical Engineering from Sacramento State University.

Len Suelter, Consultant, Engineering

Over 25 years in the cryogenic equipment industry and formerly manager of engineering for Union Carbide's cryogenic businesses.

FINANCIAL MODEL


CryoPort Inc.

	2010 A	Q1A	Q2A	Q3A	Q4E	2011 E	2012 E	2013 E	2014 E	2015 E
Total Revenues	$118.0	$151.5	$124.4	$99.6	$108.4	$483.8	$3,897.6	$24,275.3	$54,681.8	$92,617.5
YOY Growth	*235.8%*	*1005.3%*	*1367.4%*	*380.8%*	*44.4%*	*310.2%*	*705.6%*	*522.8%*	*125.3%*	*69.4%*
Cost of Revenues	$717.7	$394.5	$378.2	$256.5	$260.0	$1,289.3	$3,489.9	$12,577.3	$23,791.6	$37,500.3
Gross Income	($599.8)	($243.1)	($253.8)	($157.0)	($151.6)	($805.5)	$407.7	$11,698.0	$30,890.1	$55,117.2
Gross Margin	*-508.5%*	*-160.5%*	*-204.0%*	*-157.6%*	*-139.9%*	*-166.5%*	*10.5%*	*48.2%*	*56.5%*	*59.5%*
SG&A	$3,312.6	$943.3	$1,114.3	$1,080.8	$1,215.0	$4,353.3	$5,196.0	$8,399.2	$13,287.7	$17,504.7
% SG&A	*2808.4%*	*622.8%*	*895.7%*	*1085.4%*	*1121.1%*	*899.8%*	*133.3%*	*34.6%*	*24.3%*	*18.9%*
R&D	$284.8	$122.1	$114.5	$105.0	$98.0	$439.7	$344.0	$327.0	$340.0	$350.0
% R&D	*241.5%*	*80.6%*	*92.0%*	*105.5%*	*90.4%*	*90.9%*	*8.8%*	*1.3%*	*0.6%*	*0.4%*
Operating Income	($4,197.2)	($1,308.5)	($1,482.6)	($1,342.7)	($1,464.6)	($5,598.5)	($5,132.3)	$2,971.7	$17,262.5	$37,262.4
Operating Margin	*-3558.3%*	*-863.9%*	*-1191.7%*	*-1348.6%*	*-1351.4%*	*-1157.2%*	*-131.7%*	*12.2%*	*31.6%*	*40.2%*
Interest income, net	($7,020.5)	($135.3)	($153.5)	($147.9)	($139.0)	($575.7)	($309.0)	$12.0	$110.0	$162.0
Loss on asset sale	($9.2)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Change in derivative value	$5,577.0	$116.5	$126.3	$34.0	($20.0)	$256.9	($509.0)	($104.0)	$0.0	$0.0
Pre-Tax Income	($5,650.0)	($1,327.2)	($1,509.8)	($1,456.6)	($1,623.6)	($5,917.3)	($5,950.3)	$2,879.7	$17,372.5	$37,424.4
Taxes	$1.6	$1.6	$0.0	$0.0	$0.0	$1.6	$0.0	$345.6	$4,864.3	$12,724.3
Tax Rate	*0.0%*	*-0.1%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*12.0%*	*28.0%*	*34.0%*
Net Income	($5,651.6)	($1,328.8)	(1,509.8)	(1,456.6)	(1,623.6)	($5,918.9)	($5,950.3)	$2,534.2	$12,508.2	$24,700.1
YOY Growth	*66.2%*	*-280.0%*	*79.0%*	*-159.4%*	*186.8%*	*-4.7%*	*0.5%*	*-142.6%*	*393.6%*	*97.5%*
Net Margin	*-4791.2%*	*-877.3%*	*-1213.6%*	*-1462.9%*	*-1498.2%*	*-1223.4%*	*-152.7%*	*10.4%*	*22.9%*	*26.7%*
EPS	($1.13)	($0.16)	($0.15)	($0.11)	($0.08)	($0.45)	($0.21)	$0.05	$0.25	$0.50
YOY Growth	*-178.4%*	*-100.3%*	*90.6%*	*-121.5%*	*-12.4%*	*59.9%*	*-52.8%*	*-122.7%*	*407.9%*	*104.3%*
Diluted Shares O/S	5,011	8,146	10,269	13,565	20,363	13,086	27,884	52,290	50,820	49,112

Source: Zacks Investment Research *Brian Marckx, CFA*

© Copyright 2011, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

Zacks SCR certifies that all of the views expressed in our reports or blogs accurately reflect the personal views of the analyst or analysts contributing to the report or blog about the subject company or companies and its or their securities. We also certify that no part of an analysts' compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog.

The following disclosures relate to relationships between Zacks Investment Research ("ZIR") and Zacks Small-Cap Research ("Zacks SCR") and the companies covered by the Zacks SCR analysts in the Small-Cap Universe.

ZIR or Zacks SCR Analysts do not hold shares in the companies in which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the profitability of Zacks SCR, which includes payments received for non-investment banking revenues and services.

ZIR and Zacks SCR do not make a market in any stock. Zacks SCR has never received compensation for investment banking services on the small-cap universe. Zacks SCR does not expect received compensation for investment banking services on the small-cap universe. Zacks SCR has received compensation for non-investment banking services on the small-cap universe. Zacks SCR expects to receive additional compensation for non-investment banking services on the small-cap universe. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, and investment management.

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change. Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. Zacks SCR uses the following rating system for the securities it covers. Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution of Zacks Ratings is as follows on the 1021 companies covered: Buy/Outperform- 15.3%, Hold/Neutral- 77.9%, Sell/Underperform – 5.9%. Data is as of midnight on the business day immediately prior to this publication.

© Copyright 2011, Zacks Investment Research. All Rights Reserved.